DGIdb - FLOXURIDINE Drug Record

FLOXURIDINE chembl:CHEMBL917 ApprovedAntineoplasticImmunotherapy

Alternate Names:

5-FLUORO-2-DEOXYURIDINE
FUDR
FLUORURIDINE DEOXYRIBOSE
NSC-27640
FLOXURIDINE
F.U.D.R.
FLOXURIDINUM
FLOXIRIDINA
1-(2-DEOXY-BETA-D-RIBOFURANOSYL)-5-FLUOROURACIL
5-FLUORODEOXYURIDINE
5FDU
5-FLUOROURACIL 2'-DEOXYRIBOSIDE
FUDR®
1BETA-D-2'-DEOXYRIBOFURANOSYL-5-FLUROURACIL
DEOXYFLUOROURIDINE
FLOXIDINE
BETA-5-FLUORO-2'-DEOXYURIDINE
FDU
5-FLUOROURACIL DEOXYRIBOSIDE
1-BETA-D-2'-DEOXYRIBOFURANOSYL-5-FLUROURACIL
5-FLUORO-2-DESOXYURIDINE
2'-DEOXY-5-FLUOROURIDINE
FLOXURIDIN
5-FLUORO-2'-DEOXYURIDINE
FLUORODEOXYURIDINE
drugbank:00322
rxcui:4488
pubchem.compound:5790
chembl:CHEMBL917
chemidplus:50-91-9

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent
Drug Class	antineoplastic agents
Year of Approval	1970

(8 More Sources)

Publications:

Ghoshal et al., 2005, 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal., Mol. Cell. Biol.
Fisher et al., 1993, bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways., Cancer Res.
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Strasser et al., 2006, 5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2., Differentiation
Kubota, 1999, [Theoretical basis for low-dose CDDP/5-FU therapy]., Gan To Kagaku Ryoho
Ferguson et al., 1999, Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells., Br. J. Pharmacol.
Murakami et al., 2000, Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells., Int. J. Oncol.
Kuwa et al., Effects of a low dose leucovorin with 5-fluorouracil derivative on colorectal tumors induced with 1,2-dimethylhydrazine in rats., Anticancer Res.
Kuwa et al., Effects of long-term administration of UFT plus leucovorin on colorectal tumors induced with 1,2-dimethylhydrazine in rats., Anticancer Res.
Nambaru PK et al., 2011, Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil., Drug Metab Dispos
Cunningham et al., 1990, Development of a radioimmunoassay for neurone specific enolase (NSE) and its application in the study of patients receiving intra hepatic arterial streptozotocin and floxuridine., Clin. Chim. Acta
Hechtman et al., 2015, AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants., Mol. Cancer Res.
Muñoz-Pinedo et al., 2001, Apoptosis of haematopoietic cells upon thymidylate synthase inhibition is independent of p53 accumulation and CD95-CD95 ligand interaction., Biochem. J.

FLOXURIDINE ABCC5

Interaction Score: 1.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20930123

Sources:
DTC
FLOXURIDINE ENO2

Interaction Score: 1.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2146046

Sources:
NCI
FLOXURIDINE TYMS

Interaction Score: 1.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name CPX-1

Mechanism of Interaction Thymidylate synthase inhibitor

PMIDs:
10553409 10482907 10891536 10697524 10697523

Sources:
TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND
FLOXURIDINE FAS

Interaction Score: 0.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11115403

Sources:
NCI
FLOXURIDINE DNMT1

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15899874

Sources:
NCI
FLOXURIDINE BCL2

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8324744

Sources:
NCI
FLOXURIDINE PIK3CA

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cetuximab + Fluorouracil + Irinotecan + Floxuridine

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
25714871

Sources:
JAX-CKB
FLOXURIDINE ERBB2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17177846

Sources:
NCI
FLOXURIDINE CYP2C9

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
FLOXURIDINE CYP2C19

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
FLOXURIDINE CYP1A2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
FLOXURIDINE CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
FLOXURIDINE IDH1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
FLOXURIDINE CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC

TEND: FLOXURIDINE
- Version: 01-August-2011
Alternate Names:

FLOXURIDINE Primary Drug Name

Drug Info:

Year of Approval 1970

Drug Class antineoplastic agents

Publications:
TdgClinicalTrial: FLOXURIDINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:
NCI: FUDR
- Version: 14-September-2017
Alternate Names:

C504 NCI drug code

Drug Info:

Publications:

Muñoz-Pinedo et al., 2001, Apoptosis of haematopoietic cells upon thymidylate synthase inhibition is independent of p53 accumulation and CD95-CD95 ligand interaction., Biochem. J.

NCI: FLOXURIDINE

Version: 14-September-2017

Alternate Names:

C504 NCI drug code

Drug Info:

Publications:

Cunningham et al., 1990, Development of a radioimmunoassay for neurone specific enolase (NSE) and its application in the study of patients receiving intra hepatic arterial streptozotocin and floxuridine., Clin. Chim. Acta

NCI: 5-FLUORODEOXYURIDINE

Version: 14-September-2017

Alternate Names:

C504 NCI drug code

Drug Info:

Publications:

Ghoshal et al., 2005, 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal., Mol. Cell. Biol.

Fisher et al., 1993, bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways., Cancer Res.

DTC: FLOXURIDINE

Version: 02-September-2020

Alternate Names:

CHEMBL917 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Nambaru PK et al., 2011, Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil., Drug Metab Dispos

NCI: FLUORODEOXYURIDINE
- Version: 14-September-2017
Alternate Names:

C504 NCI drug code

Drug Info:

Publications:

Strasser et al., 2006, 5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2., Differentiation

JAX-CKB: Floxuridine

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Hechtman et al., 2015, AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants., Mol. Cancer Res.

TTD: Floxuridine
- Version: 2020.06.01
Alternate Names:

D0TS1Z TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL917
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL917
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: FLOXURIDINE
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:

Novel drug target	Established target
Trial Name	CPX-1
Mechanism of Interaction	Thymidylate synthase inhibitor

combination therapy	Cetuximab + Fluorouracil + Irinotecan + Floxuridine
Indication/Tumor Type	colorectal cancer
Response Type	sensitive

FLOXURIDINE Drug Record

FLOXURIDINE chembl:CHEMBL917 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20930123

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 2146046

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name CPX-1 Mechanism of Interaction Thymidylate synthase inhibitor

PMIDs: 10553409 10482907 10891536 10697524 10697523

Sources: TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11115403

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15899874

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8324744

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Cetuximab + Fluorouracil + Irinotecan + Floxuridine Indication/Tumor Type colorectal cancer Response Type sensitive

PMIDs: 25714871

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17177846

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

TEND: FLOXURIDINE

Alternate Names: FLOXURIDINE Primary Drug Name

Drug Info: Year of Approval 1970 Drug Class antineoplastic agents

Publications:

TdgClinicalTrial: FLOXURIDINE

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small Molecule FDA Approval approved

Publications:

NCI: FUDR

Alternate Names: C504 NCI drug code

Drug Info:

Publications: Muñoz-Pinedo et al., 2001, Apoptosis of haematopoietic cells upon thymidylate synthase inhibition is independent of p53 accumulation and CD95-CD95 ligand interaction., Biochem. J.

NCI: FLOXURIDINE

Alternate Names: C504 NCI drug code

Drug Info:

Publications: Cunningham et al., 1990, Development of a radioimmunoassay for neurone specific enolase (NSE) and its application in the study of patients receiving intra hepatic arterial streptozotocin and floxuridine., Clin. Chim. Acta

NCI: 5-FLUORODEOXYURIDINE

Alternate Names: C504 NCI drug code

Drug Info:

Interaction Types & Directionality:

n/a

PMIDs:
20930123

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
2146046

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name CPX-1

Mechanism of Interaction Thymidylate synthase inhibitor

PMIDs:
10553409 10482907 10891536 10697524 10697523

Sources:
TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

n/a

PMIDs:
11115403

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15899874

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8324744

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cetuximab + Fluorouracil + Irinotecan + Floxuridine

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
25714871

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
17177846

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Alternate Names:

FLOXURIDINE Primary Drug Name

Drug Info:

Year of Approval 1970

Drug Class antineoplastic agents

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

C504 NCI drug code

Publications:

Muñoz-Pinedo et al., 2001, Apoptosis of haematopoietic cells upon thymidylate synthase inhibition is independent of p53 accumulation and CD95-CD95 ligand interaction., Biochem. J.

Alternate Names:

C504 NCI drug code

Publications:

Cunningham et al., 1990, Development of a radioimmunoassay for neurone specific enolase (NSE) and its application in the study of patients receiving intra hepatic arterial streptozotocin and floxuridine., Clin. Chim. Acta

Alternate Names:

C504 NCI drug code

Alternate Names:

CHEMBL917 ChEMBL Drug ID

Alternate Names:

C504 NCI drug code

Publications:

Strasser et al., 2006, 5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2., Differentiation

Publications:

Hechtman et al., 2015, AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants., Mol. Cancer Res.

Alternate Names:

D0TS1Z TTD Drug ID